Risk factors of hepatocellular carcinoma--current status and perspectives
about
Tumor Necrosis Factor-α-308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-AnalysisCould metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?Eag1 channels as potential early-stage biomarkers of hepatocellular carcinomaNoncoding RNA Profiles in Tobacco- and Alcohol-Associated DiseasesGenome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, ChinaRisk prediction models for hepatocellular carcinoma in different populations.Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinomaHepatitis B virus X stimulates redox signaling through activation of ataxia telangiectasia mutated kinaseEfficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH studyGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.XPD Lys(751)Gln and Asp(312)Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian populationAssociation between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissuesDown-Regulation of MiR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study.Spontaneous rupture of multifocal hepatocellular carcinoma: case report.A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa.Pomegranate Bioactive Constituents Suppress Cell Proliferation and Induce Apoptosis in an Experimental Model of Hepatocellular Carcinoma: Role of Wnt/ β -Catenin Signaling Pathway.Mycotoxins are conventional and novel risk biomarkers for hepatocellular carcinoma.Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.Elevated ZC3H15 increases HCC growth and predicts poor survival after surgical resection.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.The Anticancer Properties and Apoptosis-inducing Mechanisms of Cinnamaldehyde and the Herbal Prescription Huang-Lian-Jie-Du-Tang ( Huáng Lián Jiě Dú Tang) in Human Hepatoma Cells.Genetic polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: a nested case-control study in Shanghai, China.Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis.miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3.Protective Assessment of Euphorbia neriifolia and its Isolated Flavonoid Against N-nitrosodiethylamine-induced Hepatic Carcinogenesis in Male Mice: A Histopathological Analysis.A Review on Dietary and Non-Dietary Risk Factors Associated with Gastrointestinal Cancer.Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.Environmental Contributions to Gastrointestinal and Liver Cancer in the Asia-Pacific Region.Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposureAssociation of hOGG1 Ser326Cys polymorphism with susceptibility to hepatocellular carcinomaAssociations of daily walking and television viewing time with liver cancer mortality: findings from the Japan Collaborative Cohort Study.In vivo antitumour potential of camel's milk against hepatocellular carcinoma in rats and its improvement of cisplatin renal side effects.Association of melatonin membrane receptor 1A/1B gene polymorphisms with the occurrence and metastasis of hepatocellular carcinoma.lincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through Notch signaling-induced epithelial-mesenchymal transition.p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.MicroRNA-337 regulates the PI3K/AKT and Wnt/β-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2.
P2860
Q26743425-A6175647-1542-412E-A01B-0F483524F048Q26824893-774CE49A-5A78-4CC9-BA98-C86172B8A811Q28069313-B0213213-6B66-4180-B37B-013449D44ECDQ28079874-07883868-1759-4626-AFF0-E5FF98FC791AQ28538135-C2EC0007-A5F5-4F1A-9A0E-8D32C2C0EBEFQ30383460-8CE7E269-8B32-44FB-A38E-920EA2BFA48BQ33618658-79F785C6-E316-421F-8B34-1830CFF30593Q33802988-334D927D-D97F-41F9-B9F6-17C41D23876CQ34458029-BBD01109-CEE2-428D-97D1-9B59FC102E43Q34693220-7F29C1D8-ACE2-43EC-A9DA-96F368BDE0C0Q35758935-AD99F1EB-8242-488F-B54A-740629B647C7Q35776681-96DAC546-4FA7-4915-8E70-EF23A3548434Q35961790-C3DDCADC-C625-4F04-B149-69B0E5D39FC0Q35982156-7D29E809-4F32-4021-A661-80127C9D5F74Q36184624-3AE12CB4-0286-4CCD-AD9D-3D5C413ECFDDQ36763380-4ABB8C66-241B-4385-94FE-B2DCC2CA9107Q36819559-77A797B5-5486-4F23-B27B-363CB33E1452Q37362644-9DABE81D-6667-472E-8054-09D2E91179F1Q37392951-26B07B52-BF41-41D9-9C22-CCBE3BDC625FQ37433645-A896D23F-CFAB-4F60-92E2-D2F536B50982Q37585346-02763DDE-D5FA-4BC5-80E3-30FAE80D40B0Q37612140-594B1ACA-B6E1-4CC1-A5D1-AE8560481697Q38103829-D1CE3394-378A-4FC3-8331-443C78FBFDB6Q38374504-32E897D4-624E-4F12-878A-2933B31FA477Q38411648-B102CE8F-F8FD-43CE-BE8A-9FB5E9E7CE17Q38645369-E5B2F928-24B6-4DA2-AF43-E98DE3EBC635Q38802250-83D9BBF3-E087-47DC-A041-F386499FC596Q38857633-62B7BC68-FE03-4B61-975B-F929274C4A97Q38996046-15CD9557-B16B-4BA4-A9A4-8A0F2F7F3C9FQ39979280-298CDF80-C0CB-4F4C-8B95-C751F06DE800Q41928159-9EA6A27E-AC9B-448D-85B4-114EDCD02C7CQ41931500-2524B6F4-1047-4438-B48F-615467BC30E1Q42535282-31FD5C6B-FFCC-4E8E-96A8-E0FCB3E67DAEQ44708294-DA366EFF-87F4-4389-9CAE-FA697C264FB2Q46391250-335FFD4F-ABF1-432D-8EB3-0592483004BEQ47442230-5B4B751A-335D-4AEE-950D-D0195C61CC79Q51654635-D6CE6F5A-07CB-4A7B-9D17-5CEB336649B9Q51761242-F9152B75-F0E0-4339-8E02-314B7BD4DB41Q52595053-34538891-99D3-4BE7-AB64-7ADB596F43F9
P2860
Risk factors of hepatocellular carcinoma--current status and perspectives
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Risk factors of hepatocellular carcinoma--current status and perspectives
@ast
Risk factors of hepatocellular carcinoma--current status and perspectives
@en
Risk factors of hepatocellular carcinoma--current status and perspectives
@nl
type
label
Risk factors of hepatocellular carcinoma--current status and perspectives
@ast
Risk factors of hepatocellular carcinoma--current status and perspectives
@en
Risk factors of hepatocellular carcinoma--current status and perspectives
@nl
prefLabel
Risk factors of hepatocellular carcinoma--current status and perspectives
@ast
Risk factors of hepatocellular carcinoma--current status and perspectives
@en
Risk factors of hepatocellular carcinoma--current status and perspectives
@nl
P2093
P1476
Risk factors of hepatocellular carcinoma--current status and perspectives
@en
P2093
P304
P356
10.7314/APJCP.2012.13.3.743
P407
P577
2012-01-01T00:00:00Z